JP2007516941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516941A5 JP2007516941A5 JP2006517455A JP2006517455A JP2007516941A5 JP 2007516941 A5 JP2007516941 A5 JP 2007516941A5 JP 2006517455 A JP2006517455 A JP 2006517455A JP 2006517455 A JP2006517455 A JP 2006517455A JP 2007516941 A5 JP2007516941 A5 JP 2007516941A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutically acceptable
- composition
- disorder
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 29
- 239000012453 solvate Substances 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 230000002265 prevention Effects 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 150000004677 hydrates Chemical class 0.000 claims 9
- 238000002560 therapeutic procedure Methods 0.000 claims 9
- 210000003169 central nervous system Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 230000003542 behavioural effect Effects 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical group FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims 4
- 229910052740 iodine Inorganic materials 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 208000032841 Bulimia Diseases 0.000 claims 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000027626 Neurocognitive disease Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims 3
- 206010041250 Social phobia Diseases 0.000 claims 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 3
- 208000025748 atypical depressive disease Diseases 0.000 claims 3
- 201000010064 diabetes insipidus Diseases 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 208000022821 personality disease Diseases 0.000 claims 3
- 201000000484 premenstrual tension Diseases 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical compound OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000020685 sleep-wake disease Diseases 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 2
- 241000287462 Phalacrocorax carbo Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 201000009941 intracranial hypertension Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- YGLDQFWPUCURIP-UHFFFAOYSA-N 3h-3-benzazepine Chemical compound C1=CNC=CC2=CC=CC=C21 YGLDQFWPUCURIP-UHFFFAOYSA-N 0.000 claims 1
- APEKSNHUILZZDC-UHFFFAOYSA-N 6,7-dichloro-3,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CC1CN(C)CCC2=CC=C(Cl)C(Cl)=C12 APEKSNHUILZZDC-UHFFFAOYSA-N 0.000 claims 1
- QXXFCLLJUAFAFV-UHFFFAOYSA-N 6-bromo-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(Cl)C(Br)=C12 QXXFCLLJUAFAFV-UHFFFAOYSA-N 0.000 claims 1
- LVDZEHWRCDOGFA-UHFFFAOYSA-N 7,9-dichloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=C(Cl)C=C(Cl)C=C12 LVDZEHWRCDOGFA-UHFFFAOYSA-N 0.000 claims 1
- LSYBMYCVSJZAMI-UHFFFAOYSA-N 7-chloro-6-fluoro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(Cl)C(F)=C12 LSYBMYCVSJZAMI-UHFFFAOYSA-N 0.000 claims 1
- HMGASYPJYKHVCW-UHFFFAOYSA-N 9-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=C(Cl)C=CC=C12 HMGASYPJYKHVCW-UHFFFAOYSA-N 0.000 claims 1
- 206010001488 Aggression Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010022773 Intracranial pressure increased Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47928003P | 2003-06-17 | 2003-06-17 | |
| US60/479,280 | 2003-06-17 | ||
| PCT/US2004/019670 WO2005003096A1 (en) | 2003-06-17 | 2004-06-16 | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011118521A Division JP2011162564A (ja) | 2003-06-17 | 2011-05-26 | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007516941A JP2007516941A (ja) | 2007-06-28 |
| JP2007516941A5 true JP2007516941A5 (enExample) | 2007-08-09 |
| JP4782003B2 JP4782003B2 (ja) | 2011-09-28 |
Family
ID=33563791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517455A Expired - Fee Related JP4782003B2 (ja) | 2003-06-17 | 2004-06-16 | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
| JP2011118521A Pending JP2011162564A (ja) | 2003-06-17 | 2011-05-26 | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011118521A Pending JP2011162564A (ja) | 2003-06-17 | 2011-05-26 | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7704993B2 (enExample) |
| EP (2) | EP2332920A3 (enExample) |
| JP (2) | JP4782003B2 (enExample) |
| KR (1) | KR101152521B1 (enExample) |
| CN (4) | CN101792417A (enExample) |
| AU (1) | AU2004253888B2 (enExample) |
| BR (1) | BRPI0411470A (enExample) |
| CA (2) | CA2529320C (enExample) |
| EA (1) | EA016558B1 (enExample) |
| IL (1) | IL172334A (enExample) |
| MX (1) | MXPA05013366A (enExample) |
| NZ (1) | NZ578503A (enExample) |
| WO (1) | WO2005003096A1 (enExample) |
| ZA (2) | ZA200510194B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| US7704993B2 (en) | 2003-06-17 | 2010-04-27 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| SI2332921T1 (sl) * | 2003-06-17 | 2016-06-30 | Arena Pharmaceuticals, Inc. | 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid |
| WO2005042490A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US8685924B2 (en) | 2004-08-25 | 2014-04-01 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| CA2589988C (en) | 2004-12-21 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
| PT1833473E (pt) | 2004-12-23 | 2009-12-17 | Arena Pharm Inc | Composições de modulador de receptor 5ht2c e métodos de utilização |
| EP1924560B1 (en) * | 2005-09-01 | 2009-08-05 | Eli Lilly And Company | 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| BRPI0615033A2 (pt) | 2005-09-01 | 2011-04-26 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| JP5249031B2 (ja) * | 2005-09-01 | 2013-07-31 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
| BRPI0615048A2 (pt) | 2005-09-01 | 2010-03-30 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| MX2008009178A (es) | 2006-01-19 | 2008-12-05 | Athersys Inc | Tiofenil y pirrolil acepinas como ligandos del receptor de serotonina 5-ht2c y sus usos. |
| EP2518053A1 (en) * | 2006-04-03 | 2012-10-31 | Arena Pharmaceuticals, Inc. | Process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
| EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| EP2099743B1 (en) | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
| CL2008000596A1 (es) * | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
| EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
| JP5491421B2 (ja) * | 2008-03-04 | 2014-05-14 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス |
| GEP20146168B (en) | 2009-06-15 | 2014-09-25 | Takeda Pharmaceuticals Co | Pyrazinooxazepine derivatives |
| CN102648170A (zh) | 2009-06-18 | 2012-08-22 | 艾尼纳制药公司 | 制备5-ht2c受体激动剂的方法 |
| US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
| US20110269744A1 (en) | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| MX2013002422A (es) * | 2010-09-01 | 2013-05-17 | Arena Pharm Inc | Sales de lorcaserina con acidos opticamente activos. |
| WO2012030957A2 (en) * | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| CN103347523A (zh) | 2010-09-01 | 2013-10-09 | 艾尼纳制药公司 | 向具有肾损伤的个体给药氯卡色林 |
| SG188363A1 (en) * | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Fast-dissolve dosage forms of 5-ht2c agonists |
| CN102895233B (zh) * | 2012-09-04 | 2015-06-24 | 苏州大学 | 苯并氮杂卓类化合物在制备预防或治疗癫痫的药物中的应用 |
| WO2014058441A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| WO2014060575A2 (en) * | 2012-10-19 | 2014-04-24 | Medichem S.A. | Process for the enantioselective synthesis of a tetrahydrobenzazepine compound |
| EA026397B1 (ru) | 2012-12-21 | 2017-04-28 | ЭйБиТи ХОЛДИНГ КОМПАНИ | Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение |
| WO2014159067A1 (en) | 2013-03-13 | 2014-10-02 | Abt Holding Company | Thienylindole azepines as serotonin 5-ht2c receptor ligands and uses thereof |
| CN103333111A (zh) * | 2013-06-14 | 2013-10-02 | 苏州汇和药业有限公司 | 氯卡色林盐酸盐的制备方法 |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2015096119A1 (zh) * | 2013-12-27 | 2015-07-02 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| WO2015170346A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | A process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine its enantiomers |
| EA022748B1 (ru) * | 2014-06-02 | 2016-02-29 | Делкростон Менеджмент Лимитед | Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением |
| CN104016919A (zh) * | 2014-06-18 | 2014-09-03 | 安徽省逸欣铭医药科技有限公司 | 一种绿卡色林类似物及其制备方法和用途 |
| CN104130188B (zh) * | 2014-08-05 | 2016-08-31 | 南京工业大学 | 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备方法 |
| CN105693610B (zh) * | 2014-11-28 | 2019-01-11 | 国药集团宜宾制药有限责任公司 | 氯卡色林中间体的制备方法 |
| HRP20192044T1 (hr) * | 2015-04-27 | 2020-02-07 | Arena Pharmaceuticals, Inc. | Agonisti i pripravci 5-ht2c receptora i metode uporabe |
| EP3328835B1 (en) * | 2015-07-31 | 2022-10-12 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN105777638B (zh) * | 2016-01-06 | 2019-07-30 | 北京修正创新药物研究院有限公司 | 氯卡色林杂质的制备方法 |
| CN106631823B (zh) * | 2016-12-20 | 2022-04-26 | 天津泰普制药有限公司 | 一种氯卡色林中间体的制备方法 |
| CN107353250B (zh) * | 2016-12-27 | 2019-11-12 | 开封制药(集团)有限公司 | 一种氯卡色林的合成方法 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| CN108358796B (zh) * | 2018-02-23 | 2021-03-23 | 广州同隽医药科技有限公司 | 一种绿卡色林关键中间体ⅰ的制备方法 |
| CN110590695B (zh) * | 2019-10-22 | 2023-03-21 | 南华大学 | 苯并氮杂环类化合物及其应用 |
| CN115784911A (zh) * | 2022-10-19 | 2023-03-14 | 山东省药学科学院 | 一种1-[2-(4-氯苯基)-乙基氨基]-2-丙醇的合成方法 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
| CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
| CH500194A (de) | 1968-02-15 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Tetrahydroazepinderivaten |
| GB1268243A (en) | 1968-03-11 | 1972-03-22 | Wallace & Tiernan Inc | 0,2,4,5,-tetrahydro-3h,3-benzazepines |
| US4233217A (en) * | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
| FR314F (enExample) | 1968-03-22 | 1970-05-25 | ||
| FR7736M (enExample) | 1968-09-02 | 1970-03-09 | ||
| US3716639A (en) * | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
| US3795683A (en) * | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
| LU65954A1 (enExample) * | 1972-08-25 | 1974-03-07 | ||
| US4210749A (en) * | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
| US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4108989A (en) * | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
| CA1090797A (en) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds |
| AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| US4477378A (en) | 1980-02-05 | 1984-10-16 | Schering Corp. | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| ZA827887B (en) | 1981-11-27 | 1983-11-30 | Smithkline Beckman Corp | Pharmaceutical compositions and method of producing alpha2 antagonism |
| DE3272044D1 (de) | 1981-11-27 | 1986-08-21 | Smithkline Beckman Corp | 3-benzazepines as alpha-2 antagonists |
| FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
| US4988690A (en) * | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
| DE3418270A1 (de) | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| EG18188A (en) * | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
| US4762845A (en) * | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
| EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| ZA882080B (en) * | 1987-03-27 | 1989-04-26 | Schering Corp | Substituted benzazepines,their preparation and pharmaceutical compositions containing them |
| US5015639A (en) * | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
| US5247080A (en) | 1987-03-27 | 1993-09-21 | Schering Corporation | Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds |
| WO1988007858A1 (en) | 1987-04-09 | 1988-10-20 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
| US4957914A (en) | 1987-05-15 | 1990-09-18 | Syntex (U.S.A.) Inc. | 1,9-alkano-bridged-2,3,4,5-tetrahydro-1H-3-benzazepines |
| DK107688D0 (da) | 1988-03-01 | 1988-03-01 | Novo Industri As | Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner |
| US5422355A (en) * | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
| US5178786A (en) * | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
| CA2037162A1 (en) * | 1990-03-12 | 1991-09-13 | Steven Howard Shaber | Heterocyclicacetonitriles and fungicidal use |
| AU8201591A (en) | 1990-06-15 | 1992-01-07 | Schering Corporation | 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them |
| US5275915A (en) * | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
| KR940701258A (ko) | 1991-06-21 | 1994-05-28 | 피터 죤 기딩즈 | 문맥압 항진증 및 편두통의 치료를 위한 테트라하이드로벤즈아제핀 유도체의 용도 |
| GB9116824D0 (en) | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
| EP0558824A1 (en) * | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof |
| JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
| JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
| AU7177694A (en) * | 1993-06-23 | 1995-01-17 | Cambridge Neuroscience, Inc. | Sigma receptor ligands and the use thereof |
| US5387685A (en) * | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| GB9322976D0 (en) * | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
| DE4419246A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419247A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
| DE4419315A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4427838A1 (de) | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
| GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
| JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
| CA2190708A1 (en) * | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
| US5892116A (en) | 1996-01-03 | 1999-04-06 | Georgetown University | Gelators |
| US5925651A (en) * | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5691362A (en) * | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| WO1998006701A1 (en) | 1996-08-15 | 1998-02-19 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| AU6290998A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
| AUPP020297A0 (en) | 1997-11-05 | 1997-11-27 | University Of Melbourne, The | A novel receptor, and compounds which bind thereto |
| US6506757B1 (en) | 1998-03-10 | 2003-01-14 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| EP0987235B1 (en) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| DE60006618T2 (de) * | 1999-08-06 | 2004-09-23 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
| DE10003708A1 (de) * | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
| IL153111A0 (en) | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| US7429579B2 (en) | 2000-11-14 | 2008-09-30 | Smithkline Beecham, Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| JPWO2002074746A1 (ja) | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| AU2002356525A1 (en) | 2001-09-24 | 2003-04-07 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| JP3813152B2 (ja) * | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| SI2332921T1 (sl) | 2003-06-17 | 2016-06-30 | Arena Pharmaceuticals, Inc. | 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid |
| US7704993B2 (en) | 2003-06-17 | 2010-04-27 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| WO2005042491A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| WO2005042490A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| CA2589988C (en) | 2004-12-21 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
| PT1833473E (pt) | 2004-12-23 | 2009-12-17 | Arena Pharm Inc | Composições de modulador de receptor 5ht2c e métodos de utilização |
-
2004
- 2004-06-16 US US10/561,071 patent/US7704993B2/en not_active Expired - Fee Related
- 2004-06-16 AU AU2004253888A patent/AU2004253888B2/en not_active Ceased
- 2004-06-16 BR BRPI0411470-1A patent/BRPI0411470A/pt active Search and Examination
- 2004-06-16 MX MXPA05013366A patent/MXPA05013366A/es active IP Right Grant
- 2004-06-16 EP EP10010300A patent/EP2332920A3/en not_active Withdrawn
- 2004-06-16 WO PCT/US2004/019670 patent/WO2005003096A1/en not_active Ceased
- 2004-06-16 NZ NZ578503A patent/NZ578503A/en not_active IP Right Cessation
- 2004-06-16 CA CA2529320A patent/CA2529320C/en not_active Expired - Fee Related
- 2004-06-16 CN CN201010003763A patent/CN101792417A/zh active Pending
- 2004-06-16 EP EP04776811A patent/EP1633720A1/en not_active Withdrawn
- 2004-06-16 JP JP2006517455A patent/JP4782003B2/ja not_active Expired - Fee Related
- 2004-06-16 EA EA200600048A patent/EA016558B1/ru not_active IP Right Cessation
- 2004-06-16 CN CN2008100073149A patent/CN101274911B/zh not_active Expired - Fee Related
- 2004-06-16 CN CN2004800167803A patent/CN1805939B/zh not_active Expired - Lifetime
- 2004-06-16 CA CA2888392A patent/CA2888392A1/en not_active Withdrawn
- 2004-06-16 CN CN2004800167733A patent/CN1805938B/zh not_active Expired - Fee Related
-
2005
- 2005-12-02 IL IL172334A patent/IL172334A/en not_active IP Right Cessation
- 2005-12-14 ZA ZA200510194A patent/ZA200510194B/en unknown
- 2005-12-15 ZA ZA200510255A patent/ZA200510255B/xx unknown
- 2005-12-16 KR KR1020057024149A patent/KR101152521B1/ko not_active Expired - Fee Related
-
2010
- 2010-03-22 US US12/729,026 patent/US8404675B2/en not_active Expired - Fee Related
-
2011
- 2011-05-26 JP JP2011118521A patent/JP2011162564A/ja active Pending
-
2012
- 2012-09-14 US US13/616,784 patent/US20130172322A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007516941A5 (enExample) | ||
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| JP2007508361A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| JP2004527467A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| JP2012006970A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2003507367A5 (enExample) | ||
| JP2003507366A5 (enExample) | ||
| CA2662000A1 (en) | Thiophene pyrazolopyrimidine compounds | |
| JP2011500658A5 (enExample) | ||
| JP2002535408A5 (enExample) | ||
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| JP2011527333A5 (enExample) | ||
| JP2011500696A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2010514829A5 (enExample) | ||
| JP2002523506A5 (enExample) | ||
| JP2017524005A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida |